Zohal Nabi

Mount Vernon Cancer Centre
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward trial nodal sub-study.

Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward trial nodal sub-study.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: March 06, 2026

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy.

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy.

Journal: The Lancet. Oncology

Published: November 14, 2025

Testing a 5-fraction Simultaneous Integrated Boost in Radiotherapy for Breast Cancer: The UK FAST-Forward Boost Trial Opens to Recruitment.

Testing a 5-fraction Simultaneous Integrated Boost in Radiotherapy for Breast Cancer: The UK FAST-Forward Boost Trial Opens to Recruitment.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: June 12, 2025

SMALL: open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer-protocol for a phase III randomised multicentre trial.

SMALL: open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer-protocol for a phase III randomised multicentre trial.

Journal: BMJ open

Published: April 09, 2025

Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study.

Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: February 09, 2025

Regional Lymph Node Delineation variability and its Dosimetric Impact in Breast Cancer Radiotherapy.

Regional Lymph Node Delineation variability and its Dosimetric Impact in Breast Cancer Radiotherapy.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: November 11, 2024

One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.

One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.

Journal: Health technology assessment (Winchester, England)

Published: November 22, 2023

POSNOC-POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes.

POSNOC-POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes.

Journal: BMJ open

Published: December 03, 2021

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.

Journal: Lancet (London, England)

Published: March 25, 2020

Provision of Organ at Risk Contouring Guidance in UK Radiotherapy Clinical Trials.

Provision of Organ at Risk Contouring Guidance in UK Radiotherapy Clinical Trials.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: April 09, 2019

Showing 1-10 of 10

Last Updated: 09/26/2026